Investment to progress RheumaGen's celiac disease program through early development as a potential transformational gene therapy PHILADELPHIA, Dec. 22, 2025 /PRNewswire/ -- Beyond Celiac Investments ...

The MarketWatch News Department was not involved in the creation of this content. The growing comprehension of the pathogenesis of celiac disease has paved the way for the exploration of alternative ...

The main treatment for celiac disease is a strict gluten-free diet. Be careful of medications with gluten, which can worsen ...

FDA grants Fast Track designation to Teva's TEV-53408, an anti-IL-15 antibody for celiac disease in Phase 2a study. Teva Pharmaceutical Industries has received Fast Track designation from the FDA for ...

According to a recent study by researchers at the University of the Basque Country (EHU), raising social awareness is ...

On the heels of new federal funding for its breakthrough immunology platform, Evoq Therapeutics has signed a global license agreement with biopharma giant Sanofi that could land the Chicago-based ...

Japan’s Takeda Pharmaceuticals and San Diego’s PvP Biologics are developing KumaMax, a novel enzyme that breaks down immune-reactive parts of gluten in the stomach, for patients with Celiac disease.

The Gluten3S research group launched a dietary intervention with children who had recently been diagnosed with celiac disease.

Research findings from the the Celiac Index partnership with the National Minority Quality Forum and Go Beyond Celiac patient registry to be presented on May 9 The abstracts highlight the importance ...

Experts have used magnetic resonance imaging (MRI) to better understand the impact a gluten free diet has on people with celiac disease, which could be the first step towards finding new ways of ...

ImmusanT, a biotechnology company, raised $20 million in funding from Vatera Healthcare Partners, a venture capital firm focusing on biopharmaceutical firms, for the development of a vaccine and ...

Investment to progress RheumaGen's celiac disease program through early development as a potential transformational gene therapy AURORA, Colo., Dec. 22, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell ...